Search

Your search keyword '"Carcinoma, Ductal, Breast therapy"' showing total 5 results
Start Over Descriptor "Carcinoma, Ductal, Breast therapy" Language russian
5 results on '"Carcinoma, Ductal, Breast therapy"'

1. [Detection and treatment of ductal carcinoma of the breast].

Author

Semiglazov VV, Tabagua TT, and Matsko DE

Subjects
Breast Neoplasms metabolism, Breast Neoplasms pathology, Carcinoma, Ductal, Breast metabolism, Carcinoma, Ductal, Breast pathology, Female, Humans, Neoplasms, Hormone-Dependent diagnosis, Neoplasms, Hormone-Dependent therapy, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Treatment Outcome, Breast Neoplasms diagnosis, Breast Neoplasms therapy, Carcinoma, Ductal, Breast diagnosis, Carcinoma, Ductal, Breast therapy
Published
2011

3. [Combination therapy of patients with locally advanced breast cancer].

Author

Manziuk LV, Komov DV, Khaĭlenko VA, Artamonova EV, Mikhina ZP, Ermilova VD, and Abashin SIu

Subjects
Adult, Antibiotics, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic administration & dosage, Antineoplastic Agents administration & dosage, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carboplatin administration & dosage, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Ductal, Breast mortality, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Carcinoma, Lobular drug therapy, Carcinoma, Lobular mortality, Carcinoma, Lobular radiotherapy, Carcinoma, Lobular surgery, Combined Modality Therapy, Doxorubicin administration & dosage, Female, Fluorouracil administration & dosage, Humans, Mammography, Mastectomy, Radical, Middle Aged, Radiotherapy Dosage, Survival Analysis, Time Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms therapy, Carcinoma, Ductal, Breast therapy, Carcinoma, Lobular therapy
Abstract

The investigation involved 30 patients with locally advanced breast cancer (T3-4N1-2M0). Combination therapy comprised two courses: carboplatin 300 mg/m2, i.v., dropwise, on day 1; doxorubicin 30 mg/m2, i.v., bolus-flow, on days 1 and 8; 5-fluorouracil 350 mg/m2, i.v., bolus-flow, on days 1 and 8, and irradiation of the breast and regional metastasis area (single target dose--2 Gy, total target dose--40 Gy). Overall clinical response was 96.7% (29/30), mammography-wise--83.3% (25/30). All patients were found operable and radical mastectomy was performed in 25. Therapeutic effect stage III-IV was histologically confirmed in 40% (25/30), stage I-II--60% (15/25). Median overall and recurrence-free survival was not reached within 36 months in 24/30, relapse-free survival was been reported in 16/24 (66.6%), tumor progression--8/24 (33.4%). Three-year; host-mastectomy recurrence-free survival--68.8 +/- 16.0%.

Published
2001

4. [Damage to breast cancer cells after the use of radiotherapy modifiers].

Author

Monakhov AG, Smirnov VP, Karev ID, Monakhova LV, and Dolotov BK

Subjects
Breast Neoplasms radiotherapy, Breast Neoplasms therapy, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast therapy, Combined Modality Therapy, Female, Humans, Microscopy, Electron, Breast Neoplasms ultrastructure, Carcinoma, Ductal, Breast ultrastructure, Hyperthermia, Induced
Published
1996

5. [Expression of epidermal growth factor receptors and their ligands in malignant tumors of the breast].

Author

Gershteĭn ES, Ermilova VD, Kuz'mina ZV, Kuzlinskiĭ NE, and Letiagin VP

Subjects
Adult, Aged, Breast Neoplasms therapy, Carcinoma, Ductal, Breast chemistry, Carcinoma, Ductal, Breast therapy, Carcinoma, Lobular chemistry, Carcinoma, Lobular therapy, Epidermal Growth Factor analysis, Female, Humans, Ligands, Middle Aged, Radioimmunoassay, Transforming Growth Factors analysis, Breast Neoplasms chemistry, ErbB Receptors analysis
Abstract

Epidermal growth factor receptors (EGFR) have been investigated in the tumors of 166 breast cancer patients and concentrations of their ligands (alpha-TGF and EGF) were measured in 104 tumors by radioimmunoassay. EGFR and both growth factors were simultaneously detected in 18% and EGFR and one of the ligands were found in 11%. There were trends to higher frequency of EGFR expression in advanced tumors, in ductal and lobular infiltrative cancers with high grade of malignancy and in estrogen receptor negative breast cancers. A possible role of the parameters studied in the prediction of breast cancer and in the choice of therapy is discussed.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results